Neuralstem in the News
FDA Approves Stem-cell Trial for ALS Patients at UM
NSI-566/ALS trial principal investigator, Eva Feldman, M.D., Ph.D., is interviewed for this article announcing FDA approval of Neuralstem’s ALS Phase II trial.
ALS Stem Cell Trial Expanding to U-M
Neuralstem’s NSI-566/ALS trial expanding to include University of Michigan, in addition to Emory, is the focus of this report on FDA approval of the Phase II trial.
FDA Clears U-M Stem Cell Clinical Trial To Recruit ALS Patients
Medical writer Robin Erb continues her NSI-566/ALS trial reporting with an overview of its next phase, Phase II, which is scheduled to include 15 patients and is now approved by the FDA.
Neuralstem: A Top Regenerative Medicine Play
An ex-scientist and professional investor and analyst provides a forward-looking overview of Neuralstem’s near-term NSI-566 trials, and reports on the company’s NSI-189/MDD Phase Ib trial currently underway.
“ALS Crisis of Conscience At FDA Spells Opportunity For Neuralstem, Brainstorm”
A Seeking Alpha contributor and biologist, working in applied sciences, writes about the recent FDA public hearing on ALS, and clinical progress in the field.
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.